GAMMA Investing
TRDA icon

GAMMA Investing’s Entrada Therapeutics TRDA Stock Holding History

GAMMA Investing’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.33K Sell
367
-158
-30% -$1.1K ﹤0.01% 3903
2026
Q2 		$3.86K Buy
525
+45
+9% +$432 ﹤0.01% 3580
2026
Q1 		$6.06K Buy
480
+385
+405% +$4.41K ﹤0.01% 3295
2025
Q4 		$977 Buy
95
+66
+228% +$556 ﹤0.01% 3795
2025
Q3 		$168 Sell
29
-255
-90% -$1.49K ﹤0.01% 3809
2025
Q2 		$1.91K Buy
284
+142
+100% +$1.14K ﹤0.01% 3417
2025
Q1 		$1.28K Buy
142
+12
+9% +$150 ﹤0.01% 3509
2024
Q4 		$2.25K Buy
130
+90
+225% +$1.63K ﹤0.01% 3185
2024
Q3 		$639 Hold
40
– – ﹤0.01% 3356
2024
Q2 		$570 Hold
40
– – ﹤0.01% 3187
2024
Q1 		$567 Buy
+40
New +$566 ﹤0.01% 3084

Other funds holding TRDA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
MassMutual Private Wealth & Trust
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CoreCap Advisors
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return

GAMMA Investing's TRDA Position: Q3 2026 in Review

GAMMA Investing reduced its Entrada Therapeutics (TRDA) stake by 30% in Q3 2026, selling an estimated $1.1K and leaving 367 shares worth $2.33K. The position accounts for ﹤0.01% of the portfolio, ranked #3903.

GAMMA Investing first reported a position in TRDA in Q1 2024 and has held it in 11 quarters since. The position peaked at $6.06K in Q1 2026. 8 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • GAMMA Investing held 367 shares of Entrada Therapeutics worth $2.33K as of Q3 2026.
  • GAMMA Investing sold 158 Entrada Therapeutics shares in Q3 2026, an estimated $1.1K.
  • Entrada Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3903 holding.
  • GAMMA Investing first reported a position in Entrada Therapeutics in Q1 2024 and has held it in 11 quarters since.
  • GAMMA Investing's Entrada Therapeutics position peaked at $6.06K in Q1 2026.
  • 8 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.